UPDATE : Monday, October 14, 2019
FDA OKs Samsung Bioepis’ Etanercept biosimilar
Samsung Bioepis has received sales approval for Eticovo (Original: Enbrel),...
by Lee Han-soo  |  2019-04-26 14:22
Foreign patients to join class-action suit against Kolon for Invossa
Foreign osteoarthritis patients expressed fury over the mislabeling of ingr...
by Jeong Sae-im  |  2019-04-25 15:39
Samsung Bioepis’ biosimilar sales in EU topped $170 million in Q1
Samsung Bioepis’ biosimilar sales in European Union surpassed $170 million ...
by Lee Han-soo  |  2019-04-25 14:07
Samsung Biologics logs ₩23.4 billion operating loss in Q1
Samsung Biologics said it posted a 23.4 billion won ($20.2 million) operati...
by Jeong Sae-im  |  2019-04-25 12:08
OECD guideline OKs Korean-developed eye irritation test
Eye irritation test developed in Korea has won the approval as the test gui...
by Lee Hye-seon  |  2019-04-22 15:33
Gene therapies’ potentials, challenges explained
Can Korea lead the global market of innovative gene therapies?Healthcare ex...
by Jeong Sae-im  |  2019-04-22 11:46
Why is TissueGene CEO silent about Invossa mislabeling?
Noh Moon-jong, CEO of Kolon TissueGene, is the key person to clarify why In...
by Jeong Sae-im  |  2019-04-19 14:37
‘How Korean pharma companies can succeed in US’
With most Korean pharmaceutical and biosimilar companies aiming to launch t...
by Lee Han-soo  |  2019-04-18 14:41
Kolon desperate to keep Invossa license amid suspicion of data fabrication
Kolon Life Science might get its sales license of Invossa-K revoked, as the...
by Lee Hye-seon  |  2019-04-18 11:16
Patients to file class-action suit against Kolon over Invossa
Local patients who got Invossa-K injection for arthritis treatment will pur...
by Jeong Sae-im  |  2019-04-17 14:58
‘Invossa lacked clinical evidence to be commercialized’
Kolon Life Science’s gene therapy Invossa-K for arthritis treatment had ina...
by Jeong Sae-im  |  2019-04-17 12:45
BIO KOREA 2019 aims to lead open innovation
BIO KOREA 2019 opened for a three-day run at COEX, southern Seoul, Wednesda...
by Lee Han-soo  |  2019-04-17 12:42
Celltrion unveils P2 trial results for influenza antibody therapy
Celltrion has presented the phase 2 clinical trial results for CT-P27, a co...
by Lee Han-soo  |  2019-04-16 16:16
‘Kolon might have fabricated data to get Invossa approval’
The regulator raised suspicion that Kolon Life Science might have tampered ...
by Jeong Sae-im  |  2019-04-16 11:07
[News Focus] Abbvie hits back at competitors selling Humira biosimilars in Europe
Abbvie is retaliating hard against the firms, which are marketing Humira’s ...
by Lee Han-soo  |  2019-04-15 15:19
All Invossa products contained 293 cells, Kolon confirms
Kolon Life Science said all of the cells used for manufacturing Invossa &nd...
by Jeong Sae-im  |  2019-04-15 11:31
Invossa license won’t be revoked: Kolon CEO
Kolon Life Science remained confident that the regulator would not nullify ...
by Jeong Sae-im  |  2019-04-12 11:40
Regulator, Kolon rebuked for slow response to Invossa problem
Late February: Kolon Life Science, Kolon TissueGene recognize mislabeled ce...
by Jeong Sae-im  |  2019-04-11 14:46
Canada OKs Celltrion’s Truxima
Celltrion said Thursday that it has received regulatory approval for Truxim...
by Lee Han-soo  |  2019-04-11 11:33
Patients may file class-action lawsuit against Kolon for mislabeling Invossa
Korean patients, who received Invossa-K injection for degenerative arthriti...
by Jeong Sae-im  |  2019-04-10 14:41
Back to Top